{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:13Z","timestamp":1792788313461,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10302104"],"award-info":[{"award-number":["2018ZX10302104"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012457","name":"Chongqing Basic and Frontier Research Project","doi-asserted-by":"publisher","award":["cstc2018jcyjAX0428"],"award-info":[{"award-number":["cstc2018jcyjAX0428"]}],"id":[{"id":"10.13039\/501100012457","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Medical Research Key Project","award":["2019ZDXM012"],"award-info":[{"award-number":["2019ZDXM012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The human neurotropic virus\n                    <jats:italic>JC Polyomavirus<\/jats:italic>\n                    , a member of the\n                    <jats:italic>Polyomaviridae<\/jats:italic>\n                    family, is the opportunistic infectious agent causing progressive multifocal leukoencephalopathy, typically in immunocompromised individuals. The spectrum of underlying reasons for the systemic immunosuppression that permits JCV infection in the central nervous system has evolved over the past 2 decades, and therapeutic immunosuppression arousing JCV infection in the brain has become increasingly prominent as a trigger for PML. Effective immune restoration subsequent to human immunodeficiency virus-related suppression is now recognized as a cause for unexpected deterioration of symptoms in patients with PML, secondary to a rebound inflammatory phenomenon called immune reconstitution inflammatory syndrome, resulting in significantly increased morbidity and mortality in a disease already infamous for its lethality. This review addresses current knowledge regarding\n                    <jats:italic>JC Polyomavirus<\/jats:italic>\n                    , progressive multifocal leukoencephalopathy, progressive multifocal leukoencephalopathy-related immune reconstitution inflammatory syndrome, and the immunocompromised states that incite\n                    <jats:italic>JC Polyomavirus<\/jats:italic>\n                    central nervous system infection, and discusses prospects for the future management of these conditions.\n                  <\/jats:p>","DOI":"10.1186\/s12981-020-00293-0","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T08:03:44Z","timestamp":1594022624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-6786","authenticated-orcid":false,"given":"Vijay","family":"Harypursat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengquan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"4","key":"293_CR1","doi-asserted-by":"crossref","first-page":"e1005574","DOI":"10.1371\/journal.ppat.1005574","volume":"12","author":"CB Buck","year":"2016","unstructured":"Buck CB, et al. The ancient evolutionary history of polyomaviruses. PLoS Pathog. 2016;12(4):e1005574.","journal-title":"PLoS Pathog"},{"issue":"3","key":"293_CR2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","volume":"26","author":"T Weber","year":"2008","unstructured":"Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26(3):833\u201354.","journal-title":"Neurol Clin"},{"issue":"4","key":"293_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.21443","volume":"64","author":"G Perez-Liz","year":"2008","unstructured":"Perez-Liz G, et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008;64(4):379\u201387.","journal-title":"Ann Neurol"},{"issue":"3","key":"293_CR4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471\u2013506.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"293_CR5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369\u201374.","journal-title":"N Engl J Med"},{"issue":"6","key":"293_CR6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00401-015-1471-7","volume":"130","author":"J Bauer","year":"2015","unstructured":"Bauer J, et al. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015;130(6):751\u201364.","journal-title":"Acta Neuropathol"},{"issue":"67","key":"293_CR7","first-page":"495","volume":"12","author":"JR Berger","year":"2011","unstructured":"Berger JR, Khalili K. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med. 2011;12(67):495\u2013503.","journal-title":"Discov Med"},{"issue":"4","key":"293_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol. 2010;9(4):425.","journal-title":"Lancet Neurol"},{"key":"293_CR9","first-page":"109","volume":"9","author":"M Kartau","year":"2019","unstructured":"Kartau M, et al. Progressive Multifocal Leukoencephalopathy: current Insights. Degener Neurol Neuromuscul Dis. 2019;9:109\u201321.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"4","key":"293_CR10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M Muller","year":"2010","unstructured":"Muller M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251\u201361.","journal-title":"Lancet Infect Dis"},{"key":"293_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz877","author":"I Sereti","year":"2019","unstructured":"Sereti I, et al. Prospective international study of incidence and predictors of immune reconstitution inflammatory syndrome and death in people with HIV and severe lymphopenia. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz877.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"293_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425\u201337.","journal-title":"Lancet Neurol"},{"issue":"1","key":"293_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rmv.710","volume":"22","author":"E Tavazzi","year":"2012","unstructured":"Tavazzi E, White MK, Khalili K. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol. 2012;22(1):18\u201332.","journal-title":"Rev Med Virol"},{"issue":"Pt 5","key":"293_CR14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1099\/vir.0.80650-0","volume":"86","author":"A Pavesi","year":"2005","unstructured":"Pavesi A. Utility of JC polyomavirus in tracing the pattern of human migrations dating to prehistoric times. J Gen Virol. 2005;86(Pt 5):1315\u201326.","journal-title":"J Gen Virol"},{"issue":"3","key":"293_CR15","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","volume":"5","author":"JM Kean","year":"2009","unstructured":"Kean JM, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.","journal-title":"PLoS Pathog"},{"issue":"1","key":"293_CR16","doi-asserted-by":"crossref","first-page":"e0186945","DOI":"10.1371\/journal.pone.0186945","volume":"13","author":"S Chalkias","year":"2018","unstructured":"Chalkias S, et al. ViroFind: a novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients. PLoS ONE. 2018;13(1):e0186945.","journal-title":"PLoS ONE"},{"issue":"5","key":"293_CR17","doi-asserted-by":"crossref","first-page":"e0155897","DOI":"10.1371\/journal.pone.0155897","volume":"11","author":"KA Wharton Jr","year":"2016","unstructured":"Wharton KA Jr, et al. JC Polyomavirus abundance and distribution in progressive multifocal leukoencephalopathy (PML) brain tissue implicates myelin sheath in intracerebral dissemination of infection. PLoS ONE. 2016;11(5):e0155897.","journal-title":"PLoS ONE"},{"issue":"3","key":"293_CR18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","volume":"81","author":"S Gheuens","year":"2010","unstructured":"Gheuens S, et al. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81(3):247\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"293_CR19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fonc.2019.00711","volume":"9","author":"L Del Valle","year":"2019","unstructured":"Del Valle L, Pina-Oviedo S. Human polyomavirus JCPyV and its role in progressive multifocal leukoencephalopathy and oncogenesis. Front Oncol. 2019;9:711.","journal-title":"Front Oncol"},{"issue":"8","key":"293_CR20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/NEN.0b013e318180e631","volume":"67","author":"L Del Valle","year":"2008","unstructured":"Del Valle L, White MK, Khalili K. Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol. 2008;67(8):729\u201340.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"293_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13550289509111006","volume":"1","author":"JR Berger","year":"1995","unstructured":"Berger JR, Concha M. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Neurovirol. 1995;1(1):5\u201318.","journal-title":"J Neurovirol"},{"issue":"4","key":"293_CR22","doi-asserted-by":"crossref","first-page":"e35793","DOI":"10.1371\/journal.pone.0035793","volume":"7","author":"X Dang","year":"2012","unstructured":"Dang X, et al. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS ONE. 2012;7(4):e35793.","journal-title":"PLoS ONE"},{"issue":"4","key":"293_CR23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/neup.12562","volume":"39","author":"D Ono","year":"2019","unstructured":"Ono D, et al. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): comparison of magnetic resonance images and neuropathology of post-mortem brain. Neuropathology. 2019;39(4):294\u2013306.","journal-title":"Neuropathology"},{"issue":"5","key":"293_CR24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ana.1004","volume":"49","author":"F Weber","year":"2001","unstructured":"Weber F, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol. 2001;49(5):636\u201342.","journal-title":"Ann Neurol"},{"issue":"4","key":"293_CR25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","volume":"14","author":"EML Williamson","year":"2017","unstructured":"Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics. 2017;14(4):961\u201373.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"293_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-107-1-78","volume":"107","author":"JR Berger","year":"1987","unstructured":"Berger JR, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107(1):78\u201387.","journal-title":"Ann Intern Med"},{"key":"293_CR27","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.16.1092","author":"KB Alstadhaug","year":"2017","unstructured":"Alstadhaug KB, Myhr KM, Rinaldo CH. Progressive multifocal leukoencephalopathy. Tidsskr Nor Laegeforen. 2017. https:\/\/doi.org\/10.4045\/tidsskr.16.1092.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"8","key":"293_CR28","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1468-1331.2011.03597.x","volume":"19","author":"MA Sahraian","year":"2012","unstructured":"Sahraian MA, et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol. 2012;19(8):1060\u20139.","journal-title":"Eur J Neurol"},{"issue":"2","key":"293_CR29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.604","volume":"102","author":"R Anton","year":"2017","unstructured":"Anton R, et al. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators\u2019 perspective. Clin Pharmacol Ther. 2017;102(2):283\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"293_CR30","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1128\/JCM.43.8.4175-4177.2005","volume":"43","author":"A Marzocchetti","year":"2005","unstructured":"Marzocchetti A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol. 2005;43(8):4175\u20137.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"293_CR31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12883-019-1476-2","volume":"19","author":"K Nakamichi","year":"2019","unstructured":"Nakamichi K, et al. Improving detection of JC virus by ultrafiltration of cerebrospinal fluid before polymerase chain reaction for the diagnosis of progressive multifocal leukoencephalopathy. BMC Neurol. 2019;19(1):252.","journal-title":"BMC Neurol"},{"issue":"7","key":"293_CR32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jnnp-2015-312037","volume":"87","author":"AM Lee","year":"2016","unstructured":"Lee AM, et al. Safety and diagnostic value of brain biopsy in HIV patients: a case series and meta-analysis of 1209 patients. J Neurol Neurosurg Psychiatry. 2016;87(7):722\u201333.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"293_CR33","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80(15):1430\u20138.","journal-title":"Neurology"},{"issue":"6","key":"293_CR34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","volume":"21","author":"DB Clifford","year":"2015","unstructured":"Clifford DB. Progressive multifocal leukoencephalopathy therapy. J Neurovirol. 2015;21(6):632\u20136.","journal-title":"J Neurovirol"},{"issue":"10","key":"293_CR35","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/598335","volume":"48","author":"N Khanna","year":"2009","unstructured":"Khanna N, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20\u00a0years of the Swiss HIV Cohort Study. Clin Infect Dis. 2009;48(10):1459\u201366.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"293_CR36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/520514","volume":"196","author":"S Verma","year":"2007","unstructured":"Verma S, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196(5):709\u201311.","journal-title":"J Infect Dis"},{"issue":"2","key":"293_CR37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneurol.2008.557","volume":"66","author":"D Cettomai","year":"2009","unstructured":"Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus\u2013infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255\u20138.","journal-title":"Arch Neurol"},{"issue":"5","key":"293_CR38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","volume":"53","author":"M Brickelmaier","year":"2009","unstructured":"Brickelmaier M, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53(5):1840\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"293_CR39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","volume":"19","author":"DB Clifford","year":"2013","unstructured":"Clifford DB, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19(4):351\u20138.","journal-title":"J Neurovirol"},{"issue":"13","key":"293_CR40","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1097\/00002030-200209060-00012","volume":"16","author":"CM Marra","year":"2002","unstructured":"Marra CM, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16(13):1791\u20137.","journal-title":"AIDS"},{"issue":"19","key":"293_CR41","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall CD, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med. 1998;338(19):1345\u201351.","journal-title":"N Engl J Med"},{"issue":"17","key":"293_CR42","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597\u2013605.","journal-title":"N Engl J Med"},{"issue":"17","key":"293_CR43","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","volume":"380","author":"S Rauer","year":"2019","unstructured":"Rauer S, et al. Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab. N Engl J Med. 2019;380(17):1676\u20137.","journal-title":"N Engl J Med"},{"key":"293_CR44","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"G Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi G, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. 2018;24:S95\u2013107.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"293_CR45","first-page":"e82","volume":"188","author":"M Uzunov","year":"2019","unstructured":"Uzunov M, et al. Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab. Br J Haematol. 2019;188(6):e82\u20134.","journal-title":"Br J Haematol"},{"key":"293_CR46","first-page":"1667","volume":"380","author":"IJ Koralnik","year":"2019","unstructured":"Koralnik IJ. Can immune checkpoint inhibitors keep JC virus in check? Mass Medical Soc. 2019;380:1667.","journal-title":"Mass Medical Soc."},{"issue":"6","key":"293_CR47","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1212\/NXI.0000000000000628","volume":"6","author":"C K\u00fcpper","year":"2019","unstructured":"K\u00fcpper C, et al. Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e628.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"293_CR48","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3201\/eid2511.190705","volume":"25","author":"C Medrano","year":"2019","unstructured":"Medrano C, et al. Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. Emerg Infect Dis. 2019;25(11):2145\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"293_CR49","doi-asserted-by":"crossref","first-page":"e0136046","DOI":"10.1371\/journal.pone.0136046","volume":"10","author":"HS Wollebo","year":"2015","unstructured":"Wollebo HS, et al. CRISPR\/Cas9 system as an agent for eliminating polyomavirus JC infection. PLoS ONE. 2015;10(9):e0136046.","journal-title":"PLoS ONE"},{"issue":"9","key":"293_CR50","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1128\/JVI.02657-08","volume":"83","author":"N Khanna","year":"2009","unstructured":"Khanna N, et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol. 2009;83(9):4404\u201311.","journal-title":"J Virol"},{"issue":"3","key":"293_CR51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/fvl.10.12","volume":"5","author":"AS Saribas","year":"2010","unstructured":"Saribas AS, et al. JC virus-induced progressive multifocal leukoencephalopathy. Future Virol. 2010;5(3):313\u201323.","journal-title":"Future Virol"},{"key":"293_CR52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","volume":"8","author":"A Fournier","year":"2017","unstructured":"Fournier A, et al. Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol. 2017;8:577.","journal-title":"Front Immunol"},{"issue":"6803","key":"293_CR53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/35035103","volume":"407","author":"ES Rosenberg","year":"2000","unstructured":"Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407(6803):523\u20136.","journal-title":"Nature"},{"issue":"11","key":"293_CR54","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/00002030-199211000-00009","volume":"6","author":"M French","year":"1992","unstructured":"French M, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS. 1992;6(11):1293\u20137.","journal-title":"AIDS"},{"key":"293_CR55","first-page":"49","volume":"7","author":"NF Walker","year":"2015","unstructured":"Walker NF, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl). 2015;7:49\u201364.","journal-title":"HIV AIDS (Auckl)"},{"issue":"9","key":"293_CR56","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/522182","volume":"45","author":"N Singh","year":"2007","unstructured":"Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis. 2007;45(9):1192\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"293_CR57","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181594c8c","volume":"46","author":"YC Manabe","year":"2007","unstructured":"Manabe YC, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46(4):456\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"293_CR58","doi-asserted-by":"crossref","first-page":"107327481772990","DOI":"10.1177\/1073274817729901","volume":"24","author":"C Bohra","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901.","journal-title":"Cancer Control"},{"issue":"143","key":"293_CR59","doi-asserted-by":"crossref","first-page":"160042","DOI":"10.1183\/16000617.0042-2016","volume":"26","author":"R Gopal","year":"2017","unstructured":"Gopal R, Rapaka RR, Kolls JK. Immune reconstitution inflammatory syndrome associated with pulmonary pathogens. Eur Respir Rev. 2017;26(143):160042.","journal-title":"Eur Respir Rev"},{"key":"293_CR60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","volume":"11","author":"T Saida","year":"2017","unstructured":"Saida T, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25\u201331.","journal-title":"Mult Scler Relat Disord"},{"key":"293_CR61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijid.2016.02.161","volume":"45","author":"G Meintjes","year":"2016","unstructured":"Meintjes G. Manifestations and management of IRIS. International Journal of Infectious Diseases. 2016;45:53\u20134.","journal-title":"International Journal of Infectious Diseases"},{"issue":"4","key":"293_CR62","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4269\/ajtmh.16-0773","volume":"97","author":"M Perez-Rueda","year":"2017","unstructured":"Perez-Rueda M, et al. Immune reconstitution inflammatory syndrome in HIV-infected immigrants. Am J Trop Med Hyg. 2017;97(4):1072\u20137.","journal-title":"Am J Trop Med Hyg"},{"issue":"17","key":"293_CR63","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","volume":"72","author":"K Tan","year":"2009","unstructured":"Tan K, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458\u201364.","journal-title":"Neurology"},{"issue":"8","key":"293_CR64","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/eji.201343632","volume":"43","author":"RP Lai","year":"2013","unstructured":"Lai RP, et al. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol. 2013;43(8):1995\u20132002.","journal-title":"Eur J Immunol"},{"issue":"5","key":"293_CR65","doi-asserted-by":"crossref","first-page":"e63541","DOI":"10.1371\/journal.pone.0063541","volume":"8","author":"G Narendran","year":"2013","unstructured":"Narendran G, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS ONE. 2013;8(5):e63541.","journal-title":"PLoS ONE"},{"issue":"13","key":"293_CR66","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1097\/QAD.0b013e32833b260a","volume":"24","author":"J Orikiiriza","year":"2010","unstructured":"Orikiiriza J, et al. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS. 2010;24(13):2009\u201317.","journal-title":"AIDS"},{"issue":"2","key":"293_CR67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00281-015-0532-2","volume":"38","author":"RP Lai","year":"2016","unstructured":"Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol. 2016;38(2):185\u201398.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"293_CR68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1468-1293.2000.00012.x","volume":"1","author":"MA French","year":"2000","unstructured":"French MA, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1(2):107\u201315.","journal-title":"HIV Med"},{"issue":"12","key":"293_CR69","first-page":"1282","volume":"11","author":"W Burman","year":"2007","unstructured":"Burman W, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis. 2007;11(12):1282\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"293_CR70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/cid\/cis899","volume":"56","author":"S Marais","year":"2013","unstructured":"Marais S, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56(3):450\u201360.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"293_CR71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/COH.0000000000000502","volume":"13","author":"NF Walker","year":"2018","unstructured":"Walker NF, et al. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS. 2018;13(6):512\u201321.","journal-title":"Curr Opin HIV AIDS"},{"issue":"12","key":"293_CR72","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.aids.0000131375.21070.06","volume":"18","author":"MA French","year":"2004","unstructured":"French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615\u201327.","journal-title":"AIDS"},{"issue":"9","key":"293_CR73","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1086\/630208","volume":"49","author":"LJ Haddow","year":"2009","unstructured":"Haddow LJ, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis. 2009;49(9):1424\u201332.","journal-title":"Clin Infect Dis"},{"issue":"16","key":"293_CR74","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"293_CR75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13550280500513325","volume":"11","author":"MA Lima","year":"2005","unstructured":"Lima MA, Koralnik IJ. New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol. 2005;11(Suppl 3):52\u20137.","journal-title":"J Neurovirol"},{"issue":"5","key":"293_CR76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/422257","volume":"190","author":"AM Elliott","year":"2004","unstructured":"Elliott AM, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1\u2014associated pleural tuberculosis. J Infect Dis. 2004;190(5):869\u201378.","journal-title":"J Infect Dis"},{"issue":"5","key":"293_CR77","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/QAD.0b013e3282f4f223","volume":"22","author":"PF Volkow","year":"2008","unstructured":"Volkow PF, et al. Life-threatening exacerbation of Kaposi\u2019s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS. 2008;22(5):663\u20135.","journal-title":"AIDS"},{"issue":"4","key":"293_CR78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/jof4040139","volume":"4","author":"S Delliere","year":"2018","unstructured":"Delliere S, et al. Understanding pathogenesis and care challenges of immune reconstitution inflammatory syndrome in fungal infections. J Fungi. 2018;4(4):139.","journal-title":"J Fungi"},{"issue":"6","key":"293_CR79","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1212\/NXI.0000000000000618","volume":"6","author":"P Anand","year":"2019","unstructured":"Anand P, et al. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e618.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"293_CR80","unstructured":"Biogen. Official Biogen Data. Available from: https:\/\/www.tysabrihcp.com\/en_us\/home\/efficacy-safety\/pivotal-trial.html."},{"issue":"4","key":"293_CR81","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375\u201381.","journal-title":"N Engl J Med"},{"issue":"4","key":"293_CR82","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med. 2005;353(4):362\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"293_CR83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","volume":"29","author":"EM Williamson","year":"2015","unstructured":"Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs. 2015;29(3):229\u201344.","journal-title":"CNS Drugs"},{"issue":"3","key":"293_CR84","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295\u2013303.","journal-title":"Ann Neurol"},{"issue":"6","key":"293_CR85","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11908-013-0378-5","volume":"15","author":"N Bahr","year":"2013","unstructured":"Bahr N, et al. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep. 2013;15(6):583\u201393.","journal-title":"Curr Infect Dis Rep"},{"issue":"12","key":"293_CR86","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","volume":"88","author":"D Landi","year":"2017","unstructured":"Landi D, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88(12):1144\u201352.","journal-title":"Neurology"},{"issue":"6","key":"293_CR87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13365-016-0449-0","volume":"22","author":"MH Werner","year":"2016","unstructured":"Werner MH, Huang D. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus. J Neurovirol. 2016;22(6):871\u20135.","journal-title":"J Neurovirol"},{"key":"293_CR88","unstructured":"WHO, World Health Organisation Official Data-2018. WHO website, 2018. http:\/\/apps.who.int\/gho\/data\/view.main.22100WHO?lang=en."},{"issue":"8","key":"293_CR89","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S2352-3018(19)30189-4","volume":"6","author":"S Prabhu","year":"2019","unstructured":"Prabhu S, Harwell JI, Kumarasamy N. Advanced HIV: diagnosis, treatment, and prevention. Lancet HIV. 2019;6(8):e540\u201351.","journal-title":"Lancet HIV"},{"key":"293_CR90","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3389\/fimmu.2019.01188","volume":"10","author":"L Krey","year":"2019","unstructured":"Krey L, et al. Severe progressive multifocal leukoencephalopathy (PML) and spontaneous immune reconstitution inflammatory syndrome (IRIS) in an immunocompetent patient. Front Immunol. 2019;10:1188.","journal-title":"Front Immunol"},{"key":"293_CR91","doi-asserted-by":"crossref","unstructured":"Berger, J.R. and E.O. Major. Progressive multifocal leukoencephalopathy. in Seminars in neurology. 1999. \u00a9 1999 by Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-2008-1040837"},{"issue":"5","key":"293_CR92","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/ene.12963","volume":"23","author":"S Sainz-de-la-Maza","year":"2016","unstructured":"Sainz-de-la-Maza S, et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol. 2016;23(5):919\u201325.","journal-title":"Eur J Neurol"},{"issue":"6","key":"293_CR93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic D, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255\u201373.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"293_CR94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11904-012-0129-5","volume":"9","author":"G Meintjes","year":"2012","unstructured":"Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr HIV\/AIDS Rep. 2012;9(3):238\u201350.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"293_CR95","doi-asserted-by":"crossref","first-page":"e00379","DOI":"10.1128\/mBio.00379-19","volume":"10","author":"J Morris-Love","year":"2019","unstructured":"Morris-Love J, et al. JC Polyomavirus uses extracellular vesicles to infect target cells. MBio. 2019;10(2):e00379.","journal-title":"MBio"},{"issue":"3","key":"293_CR96","doi-asserted-by":"crossref","first-page":"e01024","DOI":"10.1128\/mBio.01024-19","volume":"10","author":"M Santiana","year":"2019","unstructured":"Santiana M, Altan-Bonnet N. Insane in the Membrane: glial Extracellular Vesicles Transmit Polyomaviruses. MBio. 2019;10(3):e01024.","journal-title":"MBio"},{"key":"293_CR97","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.virusres.2019.03.023","volume":"265","author":"N Altan-Bonnet","year":"2019","unstructured":"Altan-Bonnet N, Perales C, Domingo E. Extracellular vesicles: vehicles of en bloc viral transmission. Virus Res. 2019;265:143\u20139.","journal-title":"Virus Res"},{"issue":"3","key":"293_CR98","first-page":"e4255","volume":"11","author":"AI Alwehaibi","year":"2019","unstructured":"Alwehaibi AI, AlJaber MI, Nahrir S. Favorable response to mirtazapine in John Cunningham virus-related gray matter lesion in a patient with human immunodeficiency virus. Cureus. 2019;11(3):e4255.","journal-title":"Cureus"},{"issue":"10","key":"293_CR99","doi-asserted-by":"crossref","first-page":"ofz374","DOI":"10.1093\/ofid\/ofz374","volume":"6","author":"A Audemard-Verger","year":"2019","unstructured":"Audemard-Verger A, et al. Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy. Open Forum Infect Dis. 2019;6(10):ofz374.","journal-title":"Open Forum Infect Dis"},{"issue":"15","key":"293_CR100","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu M, et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018;379(15):1443\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"293_CR101","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/acn3.776","volume":"6","author":"D Stefoski","year":"2019","unstructured":"Stefoski D, et al. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019;6(5):923\u201331.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-020-00293-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T20:22:12Z","timestamp":1625516532000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00293-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00293-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"8 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research for this review was conducted in the absence of any commercial, financial, or other relationships that could be construed as potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}